Cargando…

Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease

PURPOSE: (123)I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane ((123)I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT SPECT) and (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy can be used to assist in the diagnosis of patients with dement...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Soichiro, Hirao, Kentaro, Kanetaka, Hidekazu, Namioka, Nayuta, Hatanaka, Hirokuni, Hirose, Daisuke, Fukasawa, Raita, Umahara, Takahiko, Sakurai, Hirohumi, Hanyu, Haruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679785/
https://www.ncbi.nlm.nih.gov/pubmed/26233438
http://dx.doi.org/10.1007/s00259-015-3146-y
_version_ 1782405582638022656
author Shimizu, Soichiro
Hirao, Kentaro
Kanetaka, Hidekazu
Namioka, Nayuta
Hatanaka, Hirokuni
Hirose, Daisuke
Fukasawa, Raita
Umahara, Takahiko
Sakurai, Hirohumi
Hanyu, Haruo
author_facet Shimizu, Soichiro
Hirao, Kentaro
Kanetaka, Hidekazu
Namioka, Nayuta
Hatanaka, Hirokuni
Hirose, Daisuke
Fukasawa, Raita
Umahara, Takahiko
Sakurai, Hirohumi
Hanyu, Haruo
author_sort Shimizu, Soichiro
collection PubMed
description PURPOSE: (123)I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane ((123)I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT SPECT) and (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy can be used to assist in the diagnosis of patients with dementia with Lewy bodies (DLB). We compared the diagnostic value of these two methods in differentiating DLB from Alzheimer’s disease (AD). Furthermore, we evaluated whether a combination of DAT SPECT and MIBG myocardial scintigraphy would provide a more useful means of differentiating between DLB and AD. METHODS: Patients with AD (n = 57) and patients with DLB (n = 76) who underwent both DAT SPECT and MIBG myocardial scintigraphy were enrolled. The sensitivity, specificity, and accuracy of both methods as well as their combination for differentiating DLB from AD were calculated. Moreover, we examined whether symptoms of the patients with DLB were associated with the patterns of the abnormalities displayed on DAT SPECT and MIBG myocardial scintigraphy. RESULTS: The sensitivity and specificity of differentiating DLB from AD were 72.4 and 94.4 % by the heart to mediastinum ratio of MIBG uptake, 88.2 and 88.9 % by the specific binding ratio on DAT SPECT, and 96.1 and 90.7 % by their combination, respectively. The combined use of DAT SPECT and MIBG myocardial scintigraphy enabled more accurate differentiation between DLB and AD compared with either DAT SPECT or MIBG myocardial scintigraphy alone. There was a significantly higher frequency of parkinsonism in the abnormal DAT SPECT group than the normal DAT SPECT group. On the other hand, there was a higher frequency of the appearance of rapid eye movement (REM) sleep behavior disorder in the abnormal MIBG uptake group than the normal MIBG uptake group. CONCLUSION: These results suggested that using a combination of these scintigraphic methods is a useful and practical approach to differentiate DLB from AD.
format Online
Article
Text
id pubmed-4679785
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-46797852015-12-22 Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease Shimizu, Soichiro Hirao, Kentaro Kanetaka, Hidekazu Namioka, Nayuta Hatanaka, Hirokuni Hirose, Daisuke Fukasawa, Raita Umahara, Takahiko Sakurai, Hirohumi Hanyu, Haruo Eur J Nucl Med Mol Imaging Original Article PURPOSE: (123)I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane ((123)I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT SPECT) and (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy can be used to assist in the diagnosis of patients with dementia with Lewy bodies (DLB). We compared the diagnostic value of these two methods in differentiating DLB from Alzheimer’s disease (AD). Furthermore, we evaluated whether a combination of DAT SPECT and MIBG myocardial scintigraphy would provide a more useful means of differentiating between DLB and AD. METHODS: Patients with AD (n = 57) and patients with DLB (n = 76) who underwent both DAT SPECT and MIBG myocardial scintigraphy were enrolled. The sensitivity, specificity, and accuracy of both methods as well as their combination for differentiating DLB from AD were calculated. Moreover, we examined whether symptoms of the patients with DLB were associated with the patterns of the abnormalities displayed on DAT SPECT and MIBG myocardial scintigraphy. RESULTS: The sensitivity and specificity of differentiating DLB from AD were 72.4 and 94.4 % by the heart to mediastinum ratio of MIBG uptake, 88.2 and 88.9 % by the specific binding ratio on DAT SPECT, and 96.1 and 90.7 % by their combination, respectively. The combined use of DAT SPECT and MIBG myocardial scintigraphy enabled more accurate differentiation between DLB and AD compared with either DAT SPECT or MIBG myocardial scintigraphy alone. There was a significantly higher frequency of parkinsonism in the abnormal DAT SPECT group than the normal DAT SPECT group. On the other hand, there was a higher frequency of the appearance of rapid eye movement (REM) sleep behavior disorder in the abnormal MIBG uptake group than the normal MIBG uptake group. CONCLUSION: These results suggested that using a combination of these scintigraphic methods is a useful and practical approach to differentiate DLB from AD. Springer Berlin Heidelberg 2015-08-02 2016 /pmc/articles/PMC4679785/ /pubmed/26233438 http://dx.doi.org/10.1007/s00259-015-3146-y Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Shimizu, Soichiro
Hirao, Kentaro
Kanetaka, Hidekazu
Namioka, Nayuta
Hatanaka, Hirokuni
Hirose, Daisuke
Fukasawa, Raita
Umahara, Takahiko
Sakurai, Hirohumi
Hanyu, Haruo
Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease
title Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease
title_full Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease
title_fullStr Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease
title_full_unstemmed Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease
title_short Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease
title_sort utility of the combination of dat spect and mibg myocardial scintigraphy in differentiating dementia with lewy bodies from alzheimer’s disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679785/
https://www.ncbi.nlm.nih.gov/pubmed/26233438
http://dx.doi.org/10.1007/s00259-015-3146-y
work_keys_str_mv AT shimizusoichiro utilityofthecombinationofdatspectandmibgmyocardialscintigraphyindifferentiatingdementiawithlewybodiesfromalzheimersdisease
AT hiraokentaro utilityofthecombinationofdatspectandmibgmyocardialscintigraphyindifferentiatingdementiawithlewybodiesfromalzheimersdisease
AT kanetakahidekazu utilityofthecombinationofdatspectandmibgmyocardialscintigraphyindifferentiatingdementiawithlewybodiesfromalzheimersdisease
AT namiokanayuta utilityofthecombinationofdatspectandmibgmyocardialscintigraphyindifferentiatingdementiawithlewybodiesfromalzheimersdisease
AT hatanakahirokuni utilityofthecombinationofdatspectandmibgmyocardialscintigraphyindifferentiatingdementiawithlewybodiesfromalzheimersdisease
AT hirosedaisuke utilityofthecombinationofdatspectandmibgmyocardialscintigraphyindifferentiatingdementiawithlewybodiesfromalzheimersdisease
AT fukasawaraita utilityofthecombinationofdatspectandmibgmyocardialscintigraphyindifferentiatingdementiawithlewybodiesfromalzheimersdisease
AT umaharatakahiko utilityofthecombinationofdatspectandmibgmyocardialscintigraphyindifferentiatingdementiawithlewybodiesfromalzheimersdisease
AT sakuraihirohumi utilityofthecombinationofdatspectandmibgmyocardialscintigraphyindifferentiatingdementiawithlewybodiesfromalzheimersdisease
AT hanyuharuo utilityofthecombinationofdatspectandmibgmyocardialscintigraphyindifferentiatingdementiawithlewybodiesfromalzheimersdisease